Market Cap | 16.68M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -9.36M | Forward P/E | -2.10 | EPS next Y | -52.10% | 50D Avg Chg | 11.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 4.00% |
Dividend | N/A | Price/Book | 0.92 | EPS next 5Y | - | 52W High Chg | -63.00% |
Recommedations | 2.00 | Quick Ratio | 5.52 | Shares Outstanding | 11.78M | 52W Low Chg | 38.00% |
Insider Own | 4.62% | ROA | -35.95% | Shares Float | 11.24M | Beta | 0.71 |
Inst Own | 10.30% | ROE | -57.90% | Shares Shorted/Prior | 98.92K/91.88K | Price | 1.43 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 104,958 | Target Price | 6.50 |
Oper. Margin | - | Earnings Date | May 13 | Volume | 24,037 | Change | 0.70% |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
EF Hutton | Buy | Feb 16, 24 |
EF Hutton | Buy | Apr 18, 23 |